Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Contemp Oncol (Pozn) ; 28(1): 45-50, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38800532

RESUMO

Introduction: Colorectal cancer (CRC) remains a significant global health challenge, ranking among the leading causes of neoplastic mortality. Despite transformative therapeutic advances, a considerable proportion of patients are diagnosed with metastatic disease, and 15-30% of those initially presenting with early-stage CRC eventually experience recurrence. Comprehensive molecular testing, especially the evaluation of microsatellite instability and mutations in KRAS/NRAS or BRAF genes, is essential upon diagnosis of stage IV disease, guiding treatment decisions. Material and methods: This manuscript explores the mutational landscape of KRAS and NRAS in patients with CRC, employing digital polymerase chain reaction (PCR) BEAMing for the detection of mutations in liquid biopsy. Our study enrolled patients with histologically confirmed CRC and stage IV disease, focusing on identifying mutations in KRAS and NRAS genes during various stages of therapy. Results: Evaluating baseline, midline, and progression samples, we found that 66.6% maintained consistent mutational status post-disease progression, while 33.3% exhibited a shift in mutational status. The application of techniques with high sensitivity, such as BEAMing Digital PCR, is pivotal for accurate circulating tumour DNA (ctDNA) mutation detection. The study underscores the significance of continuous molecular monitoring in guiding therapeutic decisions for patients with metastatic CRC. Conclusions: Our findings contribute to our understanding of the evolving mutational landscape and the potential clinical implications of ctDNA ana- lysis in the era of personalised cancer medicine.

2.
Curr Oncol ; 30(12): 10509-10518, 2023 12 18.
Artigo em Inglês | MEDLINE | ID: mdl-38132400

RESUMO

Immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 inhibitors, have become the standard of care for many cancer types. However, they induce immune-related adverse events (irAEs), including neurotoxicity and hypophysitis. The incidence and outcomes of neurotoxicity and hypophysitis in patients treated with immune checkpoint inhibitors are not well established. We conducted a retrospective study of 812 patients with solid cancers who received immune checkpoint inhibitors at the University General Hospital of Ioannina between January 2018 and January 2023. We assessed demographic and clinical data, including the severity of symptoms, treatment regimen, other irAEs, resolution type and time, and death. Two patients experienced neurotoxicity and two hypophysitis. All four patients required inpatient administration and received corticosteroids or/and hormone replacement. Three patients responded to the initial therapy, experiencing full recovery, while one patient was corticosteroid-resistant, and immunoglobin G was administered. Two patients never received immunotherapy after their toxicity due to the severity of symptoms; one patient continued monotherapy with nivolumab, changing from combination therapy with ipilimumab-nivolumab, while the fourth patient continued his initial treatment with nivolumab. Our study suggests that the incidence of neurotoxicity and hypophysitis in patients treated with immune checkpoint inhibitors is low, but careful monitoring and prompt treatment with corticosteroids are necessary for effective management.


Assuntos
Hipofisite , Neoplasias , Humanos , Inibidores de Checkpoint Imunológico/uso terapêutico , Nivolumabe/uso terapêutico , Ipilimumab/efeitos adversos , Incidência , Estudos Retrospectivos , Neoplasias/tratamento farmacológico , Hipofisite/induzido quimicamente , Hipofisite/diagnóstico , Hipofisite/tratamento farmacológico , Corticosteroides/uso terapêutico
3.
Hormones (Athens) ; 13(4): 579-82, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25402392

RESUMO

Cases of sexual reassignment in Greco-Roman antiquity, presenting as a pubertal female to male gender transformation, are described in the "classical"literature. Textual evidence concerning a case of androgynism, garnered by Diodorus Siculus, among other similar accounts, as an odd story of gender dispute in a court of justice, is provided in the present study. A medical interpretation of the data pertaining to this case has been attempted and is herein reported. The spontaneous virilization and post-pubertal gender inversion of the specific individual appears to have been caused by a defect either in 5α-reductase type 2 or in 17ß hydroxysteroid dehydrogenase genes and consequent deficient enzymatic activity.


Assuntos
Transtornos Testiculares 46, XX do Desenvolvimento Sexual/história , Identidade de Gênero , Jurisprudência , 17-Hidroxiesteroide Desidrogenases/deficiência , 17-Hidroxiesteroide Desidrogenases/genética , 3-Oxo-5-alfa-Esteroide 4-Desidrogenase/deficiência , 3-Oxo-5-alfa-Esteroide 4-Desidrogenase/genética , Transtornos Testiculares 46, XX do Desenvolvimento Sexual/diagnóstico , Adulto , Diagnóstico Diferencial , Feminino , Mundo Grego , História Antiga , Humanos , Jurisprudência/história , Masculino , Casamento/história , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA